Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Recruiting

Phase 2

MW-IIIPhase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Sponsor:

Skingenix, Inc.

Code:

NCT01297400

Conditions

Burns

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Investigational Drug, MW-III

Silvadene® Cream 1% [Silver Sulfadiazine]

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by Skingenix, Inc. on 2025-06-03.